脑膜瘤转移:发生率与筛查范式建议
单中心回顾2009–2017年1193例脑膜瘤患者,随访4.3年,复发207例(17.4%)。28例接受转移筛查,10例影像可疑,8例活检证实转移,观察转移发生率0.67%,WHO II级2%、III级8.6%。作者建议对多次复发或有转移症状者行全身影像筛查。
要点
- 脑膜瘤转移观察发生率0.67%,随WHO分级升高而增加。
- 多次复发(中位3次)或有转移症状者应考虑全身影像筛查。
- 筛查阳性者中活检证实转移比例较高,可影响后续治疗决策。
核心结论
- 对多次复发或症状提示转移的脑膜瘤患者行全身影像可识别相当比例的颅外转移,并指导后续治疗决策。
研究设计与样本
- 单中心2009–2017年回顾性队列,纳入接受切除或立体定向放射外科治疗的脑膜瘤患者1193例。
- 28例接受胸部、腹部、盆腔CT或全身PET/CT(FDG或68Ga-DOTA-octreotate示踪剂)评估转移。
主要发现
- 1193例中WHO I级922例(77.3%)、II级236例(19.8%)、III级35例(2.9%),平均随访4.3年。
- 207例(17.4%)复发,平均复发1.8次。
- 28例筛查者中1例I级(3.6%)、16例II级(57.1%)、11例III级(39.3%);5例(17.9%)因症状筛查。
- 28例中27例(96.4%)有复发史,中位复发3次;影像可疑颅外病灶10例(35.7%)。
- 活检证实8例脑膜瘤转移(肝5、肺3、纵隔1、骨1),1例非脑膜瘤恶性肿瘤,1例活检前失访。
关键数值与推荐
- 筛查指征:有提示转移的症状性病灶,或无症状但复发大于2次、正在评估进一步治疗的患者。
临床怎么用
- 对多次复发(如中位3次)或出现颅外症状的脑膜瘤患者,可考虑胸部、腹部、盆腔CT或全身PET/CT筛查转移。
- 筛查发现可疑颅外病灶时应活检确认,以区分脑膜瘤转移与其他恶性肿瘤。
- 筛查结果可用于指导是否追加局部或全身治疗。
局限性
- 单中心回顾性设计,筛查仅限28例选择偏倚可能较大。
- 1例可疑病灶患者活检前失访,转移发生率可能被低估。
- 观察性研究未评估筛查对生存结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Extracranial meningioma metastases are uncommon, occurring in less than 1% of patients diagnosed with meningioma. Due to the rarity of meningioma metastases, patients are not routinely screened for distant disease. In this series, we report their experience with meningioma metastases and results of screening for metastases in select patients with recurrent meningiomas. METHODS: All patients undergoing resection or stereotactic radiosurgery for primary or recurrent meningioma from 2009 to 2017 at a single center were retrospectively reviewed to identify patients who were diagnosed with or underwent imaging to evaluate for systemic metastases. Imaging to evaluate for metastases was performed with CT scanning of the chest, abdomen, and pelvis or whole-body PET/CT using either FDG or 68Ga-DOTA-octreotate (DOTATATE) tracers in 28 patients. Indications for imaging were symptomatic lesions concerning for metastasis or asymptomatic screening in patients with greater than 2 recurrences being evaluated for additional treatment. RESULTS: Of 1193 patients treated for meningioma, 922 (77.3%) patients had confirmed or presumed WHO grade I tumors, 236 (19.8%) had grade II tumors, and 35 (2.9%) had grade III tumors. Mean follow-up was 4.3 years. A total of 207 patients experienced recurrences (17.4%), with a mean of 1.8 recurrences. Imaging for metastases was performed in 28 patients; 1 metastasis was grade I (3.6%), 16 were grade II (57.1%), and 11 were grade III (39.3%). Five patients (17.9%) underwent imaging because of symptomatic lesions. Of the 28 patients screened, 27 patients had prior recurrent meningioma (96.4%), with a median of 3 recurrences. On imaging, 10 patients had extracranial lesions suspicious for metastasis (35.7%). At biopsy, 8 were meningioma metastases, 1 was a nonmeningioma malignancy, and 1 patient was lost to follow-up prior to biopsy. Biopsy-confirmed metastases occurred in the liver (5), lung (3), mediastinum (1), and bone (1). The observed incidence of metastases was 0.67% (n = 8). Incidence increased to 2% of WHO grade II and 8.6% of grade III meningiomas. Using the proposed indications for screening, the number needed to screen to identify one patient with biopsy-confirmed malignancy was 3.83. CONCLUSIONS: Systemic imaging of patients with multiply recurrent meningioma or symptoms concerning for metastasis may identify extracranial metastases in a significant proportion of patients and can inform decision making for additional treatments.
引用
- Dalle Ore CL, Magill ST, Yen AJ, et al. Meningioma metastases: incidence and proposed screening paradigm. J Neurosurg. 2019. PMID: 30952122. doi:10.3171/2019.1.JNS181771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。